Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors.

ABSTRACT: Vaccination of patients against neoantigens expressed in concurrent tumors, recurrent tumors, or tumors developing in individuals at risk of cancer is posing major challenges in terms of which antigens to target and is limited to patients expressing neoantigens in their tumors. Here, we describe a vaccination strategy against antigens that were induced in tumor cells by downregulation of the peptide transporter associated with antigen processing (TAP). Vaccination against TAP downregulation-induced antigens was more effective than vaccination against mutation-derived neoantigens, was devoid of measurable toxicity, and inhibited the growth of concurrent and future tumors in models of recurrence and premalignant disease. Human CD8⁺ T cells stimulated with TAP^low dendrit

SUBMITTER: Garrido G 

PROVIDER: S-EPMC7339786 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature